Nimenrix: Uses, Side Effects, Benefits/Risks | Drugs.com
Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria meningitidis (group A, C, W-135, and Y).
- [PDF]
Nimenrix™ - Pfizer
Previously vaccinated children from 12 months of age, adolescents and adults NimenrixTM may be given as a booster dose to individuals who have previously received primary vaccination with a conjugated or plain polysaccharide meningococcal vaccine (see section 5.1).
Nimenrix - European Medicines Agency (EMA)
2014年4月4日 · Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria meningitidis (group A, C, W-135, and Y). Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection ...
Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria meningitidis
Meningococcal vaccine - Wikipedia
In June 2012, the FDA approved a combination vaccine against two types of meningococcal disease and Hib disease for infants and children 6 weeks to 18 months old. The vaccine, Menhibrix, prevents disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b.
NIMENRIX®: 1 dose given as 0.5 mL . IM. G. A MENVEO ® and NIMENRIX® are indicated for children 2-23 months of age. MENVEO®, MENACTRA® or NIMENRIX® vaccine may be used for those individuals 2 years of age and older. The National Advisory Committee on Immunization
Nimenrix® | Pfizer UK
Nimenrix is a conjugate vaccine that helps to provide protection against invasive disease caused by the bacteria Neisseria meningitidis types A, C, W-135 and Y. Invasive disease occurs when there is systemic spread of bacterium throughout the body causing serious infections such as septicaemia (blood infection) and meningitis (infection of the ...
NIMENRIX (meningococcal polysaccharide groups A, C, W-135 …
NIMENRIX (meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine) Product Information. Product Monograph (download PDF, 429KB) Patient Information (download PDF, 94KB) Canadian regulations limit the scope of information we are permitted to give on prescription drugs via the Internet or other means.
Nimenrix - Immunisation Advisory Centre
Nimenrix is a meningococcal conjugate vaccine to protect against meningococcal groups A, C, W and Y. From 1 July 2024, Nimenrix will be funded for eligible tamariki under 12 months of age as part of the special group programme.
What NIMENRIX is used for NIMENRIX is a vaccine used to help prevent meningococcal disease, caused by four types of Neisseria meningitidis bacteria (types A, C, W and Y). NIMENRIX works by causing your body to produce its own protection (or antibodies), against these types of meningococcal bacteria. NIMENRIX